Sugi Predict

Sugi Predict / Compounds / SCHEMBL693684

SCHEMBL693684

SCHEMBL693684

[c]1n[nH]c2cccc(-c3nccc4ccccc34)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 1/20 0.47
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ GLA P06280 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ HTR1A P08908 1/20 0.38
▸ HTR2A P28223 1/20 0.38
▸ HTR7 P34969 1/20 0.38
▸ HTR6 P50406 1/20 0.38
▸ MAOA P21397 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CYP2A6 P11509 1/20 0.36
▸ F12 P00748 1/20 0.36
▸ PLAU P00749 1/20 0.36
▸ NCF1 P14598 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3079936 0.82 BCHE (0.40) BCHENPC1MAPTKDM4EL3MBTL1
SCHEMBL315924 0.77 KDM4E (0.50) NPC1RAB9AMAPTKDM4EKMT2A
SCHEMBL2441443 0.77 NPC1 (0.43) BCHENPC1RAB9AMAPTKDM4E
SCHEMBL1756320 0.76 BCHE (0.33) BCHERAB9AMAPTKMT2ANPSR1
SCHEMBL158912 0.75 BCHE (0.58) BCHENPC1RAB9AMAPTKDM4E
SCHEMBL29986041 0.75 BCHE (0.58) BCHENPC1RAB9AMAPTKDM4E
SCHEMBL20237396 0.73 BCHE (0.57) BCHENPC1RAB9AMAPTKDM4E
SCHEMBL31011155 0.73 BCHE (0.57) BCHENPC1RAB9AMAPTKDM4E
SCHEMBL30332338 0.73 BCHE (0.57) BCHENPC1RAB9AMAPTKDM4E
SCHEMBL30332586 0.73 BCHE (0.57) BCHENPC1RAB9AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11905246-B2 Design, synthesis and characterization of metal organic frameworks KING ABDULLAH UNIVERSITY OF SCIENCE & TECHNOLOGY (SA) 2024-02-20 — — US disclosed
US-20240051985-A1 METTL3 MODULATORS ACCENT THERAPEUTICS INC (US) 2024-02-15 — — US disclosed
CN-117320710-A Combination therapy for fumarate-related diseases 易姆赛斯股份公司 2023-12-29 — — CN disclosed
EP-4229067-A1 METTL3 MODULATORS Accent Therapeutics, Inc. (US) 2023-08-23 — — EP disclosed
EP-4215191-A1 COMPOSITION COMPRISING A FUMARATE FOR USE IN A METHOD OF TREATING MULTIPLE SCLEROSIS Biogen MA Inc. (US) 2023-07-26 — — EP disclosed
US-20230172894-A1 COMBINATION TREATMENT FOR FUMARATE-RELATED DISEASES IMCYSE SA (BE) 2023-06-08 — — US disclosed
EP-4146190-A2 COMBINATION TREATMENT FOR FUMARATE-RELATED DISEASES Imcyse SA (BE) 2023-03-15 — — EP disclosed
US-20230027361-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2023-01-26 — — US disclosed
US-20220372040-A1 METTL3 MODULATORS ACCENT THERAPEUTICS, INC. (US) 2022-11-24 — — US disclosed
WO-2021079196-A9 METTL3 MODULATORS ACCENT THERAPEUTICS, INC (US) 2022-07-14 — — WO disclosed
US-20110171159-A1 Glycoside Derivatives and Uses Thereof NOVARTIS AG (CH) 2011-07-14 — — US disclosed
EP-2341902-A1 GLUCOSIDE DERIVATIVES AND USES THEREOF AS SGLT INHIBITORS Novartis AG (CH) 2011-07-13 — — EP disclosed
WO-2011048148-A2 GLYCOSIDE DERIVATIVE AND USES THEREOF NOVARTIS AG (CH) 2011-04-28 — — WO disclosed
WO-2011048112-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2011-04-28 — — WO disclosed
WO-2011029842-A1 SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER NOVARTIS AG (CH) 2011-03-17 — — WO disclosed
WO-2010121646-A1 HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS NOVARTIS AG (CH) 2010-10-28 — — WO disclosed
WO-2010031820-A1 GLUCOSIDE DERIVATIVES AND USES THEREOF AS SGLT INHIBITORS NOVARTIS AG (CH) 2010-03-25 — — WO disclosed
US-20090275606-A1 Heterocyclic Compounds as MEK Inhibitors NOVARTIS AG 2009-11-05 — — US disclosed
EP-1664027-A1 SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2006-06-07 — — EP disclosed
WO-2005021532-A1 SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2005-03-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230172894-A1 COMBINATION TREATMENT FOR FUMARATE-RELATED DISEASES FH, HLA-DRB1, HLA-B BCHE 2564/4885NPC1 1841/4885RAB9A 4272/4885
US-20240051985-A1 METTL3 MODULATORS METTL3, METTL16, METTL14 BCHE 3130/4885NPC1 599/4885RAB9A 2161/4885
US-20230027361-A1 METTL3 MODULATORS METTL3, METTL16, METTL14 BCHE 3168/4885NPC1 788/4885RAB9A 2137/4885
US-11905246-B2 Design, synthesis and characterization of metal organic frameworks OSTC, POF1B, ORC3 BCHE 4524/4885NPC1 4422/4885RAB9A 4390/4885
US-20220372040-A1 METTL3 MODULATORS METTL3, METTL16, METTL14 BCHE 3130/4885NPC1 599/4885RAB9A 2161/4885
US-20110171159-A1 Glycoside Derivatives and Uses Thereof SLC5A1, SLC5A2, SLC2A1 BCHE 2267/4885NPC1 155/4885RAB9A 2110/4885
US-20090275606-A1 Heterocyclic Compounds as MEK Inhibitors NRAS, BRAF, MAP3K1 BCHE 4348/4885NPC1 2784/4885RAB9A 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.